BACKGROUND/OBJECTIVES: Based on the growing evidence of risk reduction from fresh fruit and vegetable consumption and an inverse relationship between serum 25-hydroxyvitamin D (25OHD) and the risk of type 2 diabetes (T2D), we determined the benefits of regularly consuming vitamin D-enriched mushrooms in a prediabetic cohort. Exposing edible mushrooms to ultraviolet B (UVB) light increases vitamin D 2 (D 2 ) and raises serum 25OHD 2 in healthy young adults; however, their benefit to deficient prediabetics and glucose metabolism remains untested. SUBJECTS/METHODS: Forty-three prediabetic, D-deficient adults (25OHD ≤ 20 ng/ml), BMI425 were randomized to four groups consuming daily entrées containing 100 g fresh sliced cooked mushrooms prepared by a chef for 16 weeks. Two groups were fed UVB-treated mushrooms initially containing: 600 IU D 2 or 4000 IU D 2 ; each one also received one capsule of placebo daily. Two control groups were fed untreated mushrooms and D 3 dietary supplements at two label doses: 600 IU D 3 and 4000 IU D 3 . D 2 and D 3 content were analyzed in mushrooms, before and after cooking and in over-the-counter supplements. RESULTS: After 16 weeks, both D 2-UVB-mushroom entrée doses, which were significantly lower after cooking, produced modest or no increases in 25OHD 2 or total 25OHD relative to the positive control subjects who actually consumed about 1242 and 7320 IU per day of D 3 (higher than stated on the label). CONCLUSIONS: Unanticipated D 2 cooking loss from fresh UVB mushrooms and probable low absorption and/or hydroxylation may explain the smaller increase in 25OHD 2 in our prediabetic overweight/obese cohort compared with past findings in younger, healthy subjects. Moreover, no dose or vitamin D source was associated with modifying T2D risk factors.
INTRODUCTION
Recent meta-analyses examining the association between circulating levels of 25-hydroxyvitamin D (25OHD) and incident type 2 diabetes mellitus (T2D) in large diverse populations in the USA 1 and Europe 2 confirm the increased risk of disease across gender and age with serum 25OHD concentrations less than 20 ng/ml. Over 40 clinical trials show inverse correlation of vitamin D status with metabolic syndrome risk or incidence or severity of the features of this prediabetic syndrome, 3 and a growing number of prospective studies demonstrate that poor baseline 25OHD is predictive of glycemic status, insulin resistance and incident T2D; but, none of these studies identify the main source (solar or diet) of vitamin D contributing to circulating 25OHD. [4] [5] [6] [7] [8] [9] [10] [11] A recent prospective European study examining dietary intake and risk of T2D did not show a protective effect of higher intakes of vitamin D; however, throughout Europe dietary contributions to serum 25OHD are limited as is vitamin D fortification of foods. 11 In addition to diet, age, race/ethnicity and overweight/obesity are important factors associated with the risk of both vitamin D deficiency and T2D. 12, 13 Regular consumption of fresh fruits and vegetables and other plant foods has been negatively correlated to the risk of T2D. [14] [15] [16] One specific vegetable that is commonly consumed in Europe which may provide both vitamin D and unknown bioactive components also shown to be protective in T2D are edible mushrooms. Cultivated white button mushrooms provide high concentrations of vitamin D 2 from ergosterol upon exposure to ultraviolet B (UVB) light. [17] [18] [19] [20] [21] [22] UVB-exposed edible white button mushrooms have been shown in chronic rodent feeding studies to be a safe and effective source of vitamin D 2 , which is functional in support of growing bone and beneficially modulates immune response. 18, 19 In young adult men and women, mushroom-D 2 effectively increases 25OHD 2 in D-deficient young adults consuming capsules of dried extracts of UVB-exposed white button mushrooms (daily) 20 or in D-replete or insufficient young adults, fed soups containing moderate (daily) or very high concentrations of D 2 (once weekly). 21, 22 The addition of UVB-treated mushrooms to processed foods, such as canned soup in Canada, or the consumption of fresh D 2-enhanced mushrooms, currently marketed across the United States, is now promoted as an effective strategy for increasing the vitamin D intake in the general US population. However, the efficacy of this fresh produce in deficient populations with limited sun exposure and characteristic features of metabolic syndrome indicative of high T2D risk is unclear. To promote fresh UVB mushrooms, based on their high D 2 content and hypoglycemic/hypolipidemic activity in diabetic rats, 23 we first need to determine if factors such as food preparation, interfering matrix components of mushrooms (chitin and other nonabsorbed fiber) or possible physiologic factors associated with an individuals' age, race or disease risk influence vitamin D 2 or D 3 absorption. With 2012 medical costs for diabetes in the US alone exceeding an estimated $245 billion, there is a critical global need for effective and affordable dietary intervention strategies in the early stages of T2D, especially in countries without vitamin D fortification of food, where adequate sunlight is not available year-round. 24 We determined the ability of two levels of vitamin D 2 in fresh UVB-treated mushrooms to raise total and 25OHD 2 compared with control groups consuming untreated mushrooms plus similar doses of commercially available D 3 dietary supplements. This randomized, controlled, 16-week feeding trial studied a cohort of middle-aged adults with features of metabolic syndrome (prediabetes) and confirmed poor vitamin D status that were recruited from the racially diverse patient population in the Harlem neighborhood serviced by Mount Sinai Hospital, New York City. Vitamin D 3 dietary supplements were included in this trial, as well as untreated mushrooms, to serve as a positive control for the potentially inhibiting effect of the mushroom matrix components on vitamin D 3 absorption. Supplementation with vitamin D 3 is the standard of care for treatment of vitamin D insufficiency for all ages and race/ethnicities. There are significant gaps in our knowledge of dietary factors in natural foods that can influence the absorption of highly lipophilic food micronutrients like vitamin D 2 or D 3 , 25 as is the case for the nonabsorbed, fat replacement product, olestra, which significantly reduces the absorption of fat soluble vitamins including vitamin D. 26 Possibly, the nonabsorbed fiber components of mushroom cell walls may have a similar effect. Vitamin D bioavailability may be compromised with certain vegetables when they are consumed raw or incompletely digested and inefficiently released from complex food matrices. 27 We tested mushroom consumption under conditions that mimic expected home preparation of fresh market-available mushrooms. Daily meals contained fresh sliced mushrooms (untreated or UVB-treated) prepared in a variety of self-selected entrées prepared by a professional chef, frozen after cooking and delivered to subjects weekly over 4 months.
SUBJECTS AND METHODS
Nonsmoking adults 30 to 90 years of age (mean age = 49 ± 12 years), of diverse racial/ethnic backgrounds, with at least two features of metabolic syndrome (waist circumference ⩾ 102 cm in men and ⩾ 88 cm in women, blood pressure ⩾ 130/85 mm Hg or use of antihypertensive medication, HDL cholesterol o40 mg/dl in men or o 50 mg/dl in women, triglycerides ⩾ 150 mg/dl or use of medications for high triglycerides, fasting blood sugar ⩾ 100 mg/dl or use of metformin without the diagnosis of diabetes, HbA1c between 5.7 and 6.0%) were recruited in New York City from November 2011 to April 2012. All but six participants were studied during the winter to minimize seasonal influence. Potential participants were screened over the telephone by an investigator for age, smoking status, features of metabolic syndrome, exclusion criteria (given in Appendix) and willingness to comply with the protocol requirements. Individuals were asked to come to the Mount Sinai School of Medicine Clinical Research Unit (CRU) for a screening visit to determine vitamin D status after informed consent was obtained by an investigator or a certified designate of the principal investigator (PI). The protocol was approved by the Mount Sinai School of Medicine Institutional Review Board. The study was registered at clinicaltrials.gov under clinical trial number NCT01488734.
Participants were randomized in a 1:1:1:1 ratio by a blinded investigator using a computerized random number generator to one of the following four groups using a randomized block design with a block size of 16: (1) UV-treated mushrooms designed to contain 600 IU of D 2 /day and placebo capsules; (2) UV-treated mushrooms designed to contain 4000 IU of D 2 /day and placebo capsules; (3) untreated mushrooms and dietary supplements labeled as containing 600 IU cholecalciferol (D 3 ); (4) untreated mushrooms and dietary supplements labeled as containing 4000 IU D 3 .
Participants presented to the CRU in the morning after overnight fasting; anthropometric variables (weight, height and waist and hip circumferences) were measured, and blood samples were obtained. Blood samples were used to measure routine clinical laboratory analytes as well as concentrations of 25OHD, PTH, insulin, lipids, HbA 1c and hsCRP. At baseline and after 16 weeks, patients provided 24-h urine collections for the measurement of urinary calcium and phosphorus excretion, and underwent an oral glucose tolerance test with a load of 75 g of dextrose and blood sampling at 0, 60 and 120 min for the measurement of glucose and insulin.
Circulating concentrations of total 25OHD, 25OHD 2 and 25OHD 3 were measured at baseline, after 16 weeks of treatment and 1 month after the end of the intervention period (which was the last study visit for all study subjects). Two analytical methods were used; one to initially screen study candidates for vitamin D status (RIA) and another was used at baseline, after 16 weeks and after 1-month follow-up (LC/MS/MS) to determine the vitamin D 2 bioavailability from mushrooms and possible effects of mushrooms on vitamin D 3 absorption. The methods used in these analyses include: (1) RIA (DiaSorin, Stillwater, MN, USA), which measures total 25OHD or the sum of 25OHD 2 +25OHD 3, and (2) Liquid chromatography/tandem mass spectrometry (LC/MS/MS) performed by Quest Diagnostics, New York City, NY, USA, which differentiates 25OHD 2 and 25OHD 3, measuring each individually. UVB-treated mushrooms were exposed to UVB light at Giorgio Foods, Inc. (Temple, PA, USA) post harvest using a pulsed UV curing system (Xenon Corporation, Wilmington, MA, USA) according to the method of Kalaras et al. 17 The vitamin D 2 content of the raw mushrooms post harvest UVB exposure and after homogenization of the prepared duplicate entrées was determined by HPLC (Silliker, Inc. Illinois Laboratory, Chicago Heights, IL, USA). 28 Study subjects were asked to eat one meal a day (for 16 weeks) containing an entrée with a weighed quantity (100 g) of fresh sliced cooked mushrooms (UV-treated or untreated) prepared in a variety of self-selected entrées by a professional chef (Top Chef Meals, Westchester, NY, USA). A duplicate meal, not intended for consumption, was prepared, homogenized and aliquots sent for analyses to monitor losses of vitamin D 2 with cooking. Shown in Figure 1 , prepared meals with mushroom entrées were frozen after cooking and delivered frozen to the participants at their home on a weekly basis over four months. Participants thawed and reheated the meals by microwave; however, unlike the meal preparations, we were unable to standardize the microwave exposure used by the study participants. Participants were blinded as to the vitamin D content of the mushrooms contained in their meals or the placebo/D 3 capsules.
Commercially available D 3 supplements and identical placebo capsules were purchased via the internet (Solgar (Leonia, NJ, USA), vitamin D 3 -600 IU and Carlson Labs (Arlington Heights, IL, USA), Solar D Gems Natural Vitamin D 3 -4000 IU). All capsules (D 3 and placebo) were dispensed to the study participants blindly through the Mount Sinai Hospital Pharmacy. Vitamin D content of D 3 and placebo capsules was measured by HPLC (Silliker, Inc. Illinois Laboratory, Chicago Heights, IL, USA). All secondary outcomes such as serum calcium, lipids, insulin, HbA1 c , hsCRP and PTH were performed in the hospital clinical laboratory by standard methods.
Statistics
Initial power calculations based on a conservative estimate of the standard deviation (10 ng/ml) indicated that a sample size of 10 per group would be sufficient to detect a difference in serum 25OHD levels of 10 ng/ml from baseline to 4 months with 80% power. Statistical analysis was performed using SPSS version 19 (Chicago, IL, USA). Data are reported as means and standard deviations for continuous variables and as percentages of total for categorical variables, unless otherwise specified. Group characteristics were compared using χ 2 or Fisher's exact tests for categorical variables, and analysis of variance for continuous variables, with post hoc Tukey or Scheffe tests, as indicated. Changes in 25OHD over time, in each group, were assessed by paired t-tests. A P-value o0.05 was considered statistically significant. All data analyses were performed by an investigator blinded to treatment assignment.
RESULTS
Of the 98 subjects screened for 25OHD deficiency, 43 met the study criteria (25OHD ≤ 20 ng/ml) and were randomized into the four groups. The baseline demographics of each randomization group are given in Table 1 . Seven participants dropped out after randomization (group 1 = 2, group 2 = 0, group 3 = 3 and group 4 = 2); 36 participants completed the study. The study design and vitamin D content of the mushrooms, placebo and D 3 capsules D2 bioavailability from mushrooms in prediabetics A Mehrotra et al analyzed over the course of the study and their deviation from the target dose are shown in Figure 1 .
The mean baseline total 25OHD of the cohort was 17.0 ± 6.4 ng/ml, and there was no difference between randomization groups for any parameters, except area-under-the-curve glucose during baseline OGTT (Table 1) . Consumption of the high-dose UVBtreated mushrooms caused a modest, but significant increase in serum 25OHD 2 over time (2.5 ± 1.2 ng/ml to 9.3 ± 8.3 ng/ml, Po 0.05), whereas 25OHD 3 and total 25OHD concentrations remained unchanged (17.0 ± 4.9 ng/ml to 18.5 ± 4.1 ng/ml) ( Table 1) . No secondary outcome or metabolic syndrome variable (risk factor) showed beneficial changes with any vitamin D treatment over time (Table 1) . Circulating levels of hsCRP and 24-h urine excretion of calcium and phosphorus did not change significantly during the study (data not shown).
Consumption of the low-dose UVB-treated mushrooms did not lead to a significant change in 25OHD 2 or 25OHD 3 ( Table 1) . Consumption of the D 3 supplements at both doses caused a significant increase in serum 25OHD 3 over time, with no change in 25OHD 2 , but an increase in total 25OHD (16.1 ± 3.5 to 28.5 ±1.1 ng/ml in the low dose and 18.8 ± 4.2 to 32.5 ± 3.8 ng/ml in the high dose). Serum concentrations of 25OHD 2 and 25OHD 3 , as measured by LC/MS/MS, at baseline, 16 weeks and 1 month after the end of the intervention are shown in Figure 2 . Of note, 25OHD 2 dropped by 1 month after the end of the intervention in the high-dose UVBtreated mushroom group, whereas 25OH D 3 remained high in the D 3 -treated groups. This drop in 25OHD 2 may reflect the withdrawal of a dietary source of vitamin D 2 and/or the significantly faster clearance rate of 25OHD 2 from the circulation compared with 25OHD3. 29 
DISCUSSION
The focus of this study was not simply to determine the efficacy of D 2 in mushrooms to raise 25OHD concentrations over time, but also, to explore the effects of vitamin D combined with the possible health benefits of the bioactive ingredients in mushrooms on risk factors in glucose metabolism. 23 We used daily supplementation with D 3 as a positive control for the effects on glucose metabolism to assure that any changes were not isoformspecific and to possibly determine bioavailability problems associated with prediabetes and/or the influence of high fiber from mushroom matrices. Vitamin D 2 has been criticized for its use as a dietary supplement based on studies showing poor efficacy in maintaining 25OHD concentrations over time; 29, 30 yet, recent studies show equivalency of D 2 and D 3 supplements when taken daily in similar high doses. 31, 32 As a component of foods, whether natural or fortified, vitamin D 2 has a long history of equivalency to vitamin D 3 33 and has been shown to be equivalent to D 3 when similar doses are used to supplement breast fed infants 34 or in fortified food consumed by adults. 35 Moreover, single-nutrient dietary supplements differ from food sources in that they offer little or no other nutrients or non-nutrient benefits as do bioactive matrix components of foods like mushrooms. 23 Our intention was to test mushroom consumption in a vulnerable population of older adults, under conditions that would mimic the high heat impact of sautéing or stir frying, most frequently used in home preparation of fresh market-available mushrooms. For these reasons, mushrooms were subjected to the rigors of cooking, freezing and thawing before analyses for D 2 content. Although D 2 content of UVB light-exposed fresh mushrooms was previously shown to be stable during cold D2 bioavailability from mushrooms in prediabetics A Mehrotra et al storage 36 and with only minor loss in soup preparation and possibly less rigorous sautéing of fresh sliced mushrooms; 22 we identified appreciable losses when the mushrooms were subjected to what we presumed to be usual methods of household meal preparation. The loss reduced the daily dose levels to approximately 500 and 2600 IU/day from fresh (raw) analyzed values of 791 and 4472 IU/day, respectively. In contrast, the dietary supplements purchased through the internet contained analyzed concentrations of D 3 that were twofold higher than the target and label values, confirming recent reports of significant inaccuracies in over-the-counter vitamin D dietary supplements. 37 The vitamin D 2 doses in the daily entreés were approximately 80 and 65% of the target values; whereas the vitamin D 3 D2 bioavailability from mushrooms in prediabetics A Mehrotra et al supplements were almost 200% higher, as shown in Figure 1 . The unanticipated loss of D 2 after meal preparation together with the 420% higher D 3 content than the label declaration on the purchased D 3 supplements, present a serious problem for our comparisons and interpretation of bioavailability from either source and prevent detection of possible inhibitory effects of the mushroom fiber content on D absorption or possible interference with enterohepatic circulation of 25OHD, 38 although the later mechanism is controversial. 25 Not surprising, the higher D 3 supplement doses were significantly more effective in raising total 25OHD concentrations; however, in general, the average increase in our study cohort was less than those observed in healthy younger subjects, 29 but it is not clear what this difference could be attributed to.
At doses of 352 and 684 IU D 2 from UVB mushrooms consumed daily in soup, Stephensen et al. 22 observed 25OHD 2 mean (± s.d.) increases of 5.5 ±5.1 and 5.1 ± 1.5 ng/ml after only 6 weeks of consumption by younger (group mean ages ranged from 22.7 to 37.3 years), vitamin D-replete (~30 to 440 ng/ml total 25OHD at baseline), sun exposed (mushrooms fed June to August at 38.6°N latitude), healthy (group mean BMI range 22.1-24.5) men and women. Our older, racially diverse subjects with metabolic syndrome and poor vitamin D status achieved smaller increases in 25OHD 2 concentrations of 2.2 and 6.8 ng/ml at higher doses (500 and 2600 IU D 2 ) after 16 weeks. These differences in study results underscore the age, race, environmental and physiologic factors that may influence absorption and metabolism of vitamin D that need to be considered in testing efficacy of different food sources.
The two earlier studies with vitamin D 2 -enriched mushrooms fed in daily doses or once weekly 21, 22 reported approximately twofold higher 25OHD 2 changes from baseline in young (mean age o 30 years) healthy adults with BMI ranges of 21-25. In both of these studies, mushrooms were largely prepared and fed as a soup or less often as fresh sliced sautéed mushrooms added to an entrée prepared daily 22 and did not go through the freeze-thaw or cooking actions, as in the current study. There is an advantage to preparing the mushrooms as a soup, which would help to physically break down the cell structure (chitin cell walls of mushrooms) increasing nutrient release, unlike the larger slices of mushroom that were used in our prepared entrées. Recently, the greater bioavailability of vitamin D 2 from encapsulated dried mushroom extracts was reported to increase baseline 25OHD 2 concentrations by an average of 18 ng/ml. 20 Drying, pulverizing and extracting the mushrooms and feeding the encapsulated dried extract would markedly improve the bioavailability of vitamin D 2 and explain, in part, the greater changes in 25OHD 2 from baseline; 20 but, this extensive processing would likely cause these products to be classified as dietary supplements containing novel ingredients, not natural food sources of vitamin D.
After 16 weeks of feeding, we saw no improvement in any measurement of glucose metabolism or other feature of metabolic syndrome with either vitamin D 2 mushrooms or D 3 supplement treatments. It could be argued that this was not of sufficient duration of exposure or high enough doses for either D isoform to effectively improve glucose metabolism; or, that our study was not sufficiently powered to detect these changes. Failure to see changes in insulin sensitivity even with the highest D 3 dose may be due to the group not achieving a sufficiently high enough concentration of 25OHD. Von Hurst et al. 39 showed improvements with vitamin D 3 supplementation only when 25OHD reached 32 ng/ml or higher, concentrations that are far above the final group mean even in our highest D 3 -fed group.
A number of limitations likely prevented our demonstrating possible benefits of D-enhanced mushroom consumption in deficient prediabetics including small sample size with limited power to detect small changes in 25OHD over time, unanticipated cooking loss of D 2 and significantly higher D 3 content of over-thecounter supplements. Indeed the fact that we did not measure In conclusion, our study findings reveal many knowledge gaps with respect to our understanding of the interaction between natural food sources and vitamin D bioavailability, an area that warrants further study with respect to vitamin D's role in disease prevention, particularly if dietary guidelines continue to urge securing our micronutrient needs primarily from foods.
